The Oncologist Community

Oncology online community.
Dedicated to sharing experience and best practices. #oncology #MedTwitter

[Tom Powles @tompowles1]

Molecular classification of renal cancer (7 groups). 1+2=angiogenesis (PBRM1 rich). 3+4 = immune and cell cycle rich. Group 5 +6 proliferative (p53 CDK2NA) = new therapies needed . Personalised randomised trials are possible.

[Christian Rolfo @ChristianRolfo]

Congrats @florian_krammer and all the @IcahnMountSinai for this great paper! @OncoAlert

[Ben Derman @bdermanmd]

1) Only for t(11;14), consider + PI
2) A t(11;14) at diagnosis should be canonical - if (-) at relapse, ven should act similarly.
3) Consider an azole & halve the dose of ven.
4) Be ready for a rapid response (weeks)
5) Responses wane (~1 year) - what's the next step? #mmsm

[JeeSuk Chang @changjeesuk1]

Final results of KROG0806: IMNI in node positive BC (presented by @hkbyun_ at 2020 KOSRO). First rad_onc multicenter ph3 RCT in Korea. So proud of Chang-ok Suh (PI) and Yong Bae Kim, my mentors for conducting this trial for 12 years from scratch. 👍👏🙏

[Ahmed Abdalla @AhmedAb80025119]

Simplified algorithm for stage 4 NSCLC, feedback appreciated.

[Kohei shitara @KoheiShitara]

ENHERTU/Trastuzumab deruxtecan Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer. Good to have more treatment options ! #stomachcancer #FDA https://t.co/skycqsMrFx

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️Just in👉Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies @myESMO @ESMO_Open @notahedge https://t.co/cFW0wvcq2N

[Piet Ost @piet_ost]

Adding radiotherapy to immunotherapy improves OS and doubles out-of-field "abscopal" responses in #NSCLC. https://t.co/Aka79WnNja. Our tumor agnostic Belgian CHEERS-trial (https://t.co/L0YQg8F2uW) finished accrual today @komop_tgkanker. Let us hope we can confirm these findings

[Andrea Apolo, M.D. @apolo_andrea]

⁦@FDAOncology⁩ Grants Priority Review to #Nivolumab + #Cabozantinib for Advanced 1L #RCC treatment based on Checkmate9ER which showed improvement in OS and doubling of PFS (16.6 vs 8.3 mo) & ORRs (55.7 vs 27.1%) vs. sunitinib ⁦@DrChoueiri⁩ ⁦ https://t.co/VloZi1UQxd

[Toni Choueiri, MD @DrChoueiri]

Very elegant work from @decarvalho_lab @Pari_Mehdipour here in @nature suggesting that combining epigenetic therapies with ADAR1 inhibitors could be a promising cancer treatment. Could this strategy revive epigenetic therapies?
https://t.co/s0m5LyEuJP

[Enrique Soto @EnriqueSoto8]

We KNOW that the Geriatric Assessment is useful in oncology, AND guideline-recommended.
But are people actually using it❓
The @ASCO #gerionc taskforce conducted a global survey which is now published in @ASCO_pubs JCO-OP.
Check it out here 👇👇
https://t.co/QP2vYMc22i

[Filippo Alongi @alongi_filippo]

How radiation oncology is changing💡? 1.5 T MRlinac-guided SABR for isolated abdominal metastasis: check as never before radiation delivery on target 🎯 in high quality and in real time! #radonc #mrlinac #igrt #oligomets #adaptiveRT

[Vincent Rajkumar @VincentRK]

Spanish study finds higher mortality risk among myeloma patients hospitalized for COVID. @mvmateos #BCJ
Blood Cancer Journal

#WearAMask #StaySafe
https://t.co/E3SU73USay

[JorgKleeff @JorgKleeff]

Routine drains not necessary in liver surgery – same as for pancreatic surgery
Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese … https://t.co/Q7SGr9IiSY

[Ian Daniels FRCS @bottomdoc]

An important part of the informed consent process - outlining how long a “temporary stoma” may be temporary

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

If you are a top expert in your field, you have a tremendous power to uplift early career people with just a few words of encouragement. After my #ESMO20 talk, I received an email from Prof Fatima Cardoso congratulating me on my talk. It meant so much to me. Some thoughts 1/

[Christine Lovly, MD, PhD, FASCO @christine_lovly]

New precision therapy targeting DNA damage responses - @CD_AACR @AACR @royalmarsdenNHS @ICR_London
First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors https://t.co/cDNB4XQo15

[Dr. Iván R. González @Dr_Ivanoncologo]

#Osimertinib in Resected EGFR-Mutated #NSCLC
https://t.co/sLymZ2bk6a
#ADAURA

[Nathan A. Pennell MD, PhD, FASCO @n8pennell]

Does anyone know the evidence behind aggressively checking and replacing potassium daily in hospitalized patients? It’s like 30% of what interns do so I imagine it must save millions of lives per year.